$1.16 Billion in Sales Expected for Agilent Technologies Inc (A) This Quarter
Wall Street analysts predict that Agilent Technologies Inc (NYSE:A) will report $1.16 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.17 billion and the lowest estimate coming in at $1.15 billion. Agilent Technologies posted sales of $1.07 billion during the same quarter last year, which suggests a positive year over year growth rate of 8.4%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, February 14th.
According to Zacks, analysts expect that Agilent Technologies will report full year sales of $1.16 billion for the current financial year, with estimates ranging from $4.74 billion to $4.79 billion. For the next year, analysts expect that the company will post sales of $5.02 billion per share, with estimates ranging from $4.98 billion to $5.10 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Agilent Technologies.
Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.59 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year.
Agilent Technologies (NYSE:A) traded up $1.36 during mid-day trading on Friday, reaching $69.70. The company’s stock had a trading volume of 3,637,470 shares, compared to its average volume of 2,210,000. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.85 and a current ratio of 3.30. Agilent Technologies has a twelve month low of $50.09 and a twelve month high of $75.00. The stock has a market capitalization of $22,510.00, a price-to-earnings ratio of 33.35, a price-to-earnings-growth ratio of 2.07 and a beta of 1.28.
In related news, CFO Didier Hirsch sold 12,964 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $69.00, for a total transaction of $894,516.00. Following the sale, the chief financial officer now owns 184,851 shares of the company’s stock, valued at $12,754,719. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $68.77, for a total value of $1,546,018.37. Following the sale, the chief executive officer now directly owns 336,637 shares in the company, valued at approximately $23,150,526.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 219,991 shares of company stock worth $15,468,795.
A number of hedge funds have recently modified their holdings of the stock. Advisor Group Inc. boosted its holdings in Agilent Technologies by 0.3% in the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock worth $235,000 after acquiring an additional 10 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Agilent Technologies by 0.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 18,394 shares of the medical research company’s stock worth $1,091,000 after acquiring an additional 149 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Agilent Technologies by 3.4% in the second quarter. HighTower Advisors LLC now owns 13,318 shares of the medical research company’s stock worth $793,000 after acquiring an additional 443 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in Agilent Technologies by 1.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 48,835 shares of the medical research company’s stock worth $3,385,000 after acquiring an additional 771 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC boosted its holdings in Agilent Technologies by 7.3% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 11,406 shares of the medical research company’s stock worth $764,000 after acquiring an additional 773 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: “$1.16 Billion in Sales Expected for Agilent Technologies Inc (A) This Quarter” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/02/14/1-16-billion-in-sales-expected-for-agilent-technologies-inc-a-this-quarter.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.